RICHLAND, WA and CORALVILLE, IA – October 18, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based...
By Brian J. Moran, M.D. FABSMedical Director, Prostate Cancer Foundation of Chicago I am a radiation oncologist who, like many of you, has always looked for opportunities to do more for those I treat. That is how I first learned about Cesium-131 brachytherapy. In the...
RICHLAND, WASHINGTON – September 28, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. (Viewpoint)...
Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 21, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call...
By CEO Lori Woods Prostate Cancer Awareness Month carries more than the obvious meaning. Of course, its intent is to raise awareness in hopes that we will motivate more men to get screened because we know all too well how that can impact lives. For us, it is also an...
RICHLAND, WASHINGTON – June 21, 2022 – The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference...
RICHLAND, WASHINGTON – June 15, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a lunch symposium featuring Dr. Stephen J. Frank of the MD Anderson Cancer Center at the...
By Dr. Ronald M. BenoitDepartment of Urology, University of Pittsburgh School of Medicine Why would a clinician be hesitant to use Cesium-131 to treat prostate cancer? I would venture to say the likely answer is the data that speaks to its benefits has not yet...
Revenue Increased 12% Year-Over-Year Record Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, WASHINGTON – May 10, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced its...
Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – April 29, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to...
Isoray to Participate in the Oppenheimer 32nd Annual Healthcare Conference RICHLAND, WASHINGTON – March 10, 2022 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy, today announced that Chief Executive Officer Lori...
Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131 RICHLAND, WASHINGTON – March 2, 2022 – Investigators from the University of Pittsburgh School of Medicine have published a clinical study that demonstrates...